Skip to main content
Side panel
Bascom Palmer
SPECIALTIES
Cataracts and Intraocular Lenses
Comprehensive Ophthalmology
Corneal and External Diseases
Glaucoma
Neuro-Ophthalmology
Ocular Oncology
Ophthalmic Pathology
Ophthalmic Plastic and Reconstructive Surgery
Pediatric Ophthalmology and Strabismus
Retina and Vitreous Diseases
Uveitis
FILTER BY
Online Grand Rounds
Medical Student Education
Ophthalmic Images
Other Lectures
Surgical Videos
SEARCH
Search
Close
Search
Toggle search input
guest access (
Log in
)
Best of Angiogenesis, Exudation, and Degeneration 2024 – Virtual Edition
Home
Courses
Retina and Vitreous Diseases
Angio020324
Description
LIGHTSITE III 24-Month Analysis: Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration by Eleonora M. Lad, MD, PhD
LIGHTSITE III 24-Month Analysis: Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration by Eleonora M. Lad, MD, PhD
Click
https://youtu.be/m8bvxbUMiUs
link to open resource.
Angio020324
Description
Home
Search
Specialties
Cataracts and Intraocular Lenses
Comprehensive Ophthalmology
Corneal and External Diseases
Glaucoma
Neuro-Ophthalmology
Ocular Oncology
Ophthalmic Pathology
Ophthalmic Plastic and Reconstructive Surgery
Pediatric Ophthalmology and Strabismus
Retina and Vitreous Diseases
Uveitis
Filter By
Grand Rounds
Medical Student Education
Ophthalmic Images
Other Lectures
Surgical Videos
Search
About Us
◄ Ophthalmic Artery Angioplasty for GA: Rationale, Perspectives, and Early Outcomes by Mario J. Saravia, MD, PhD
Jump to...
Jump to...
Philip J. Rosenfeld, MD, PhD
Harry W. Flynn, Jr., MD
Thomas A. Albini, MD
Ophthalmic Artery Angioplasty for GA: Rationale, Perspectives, and Early Outcomes by Mario J. Saravia, MD, PhD
First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD by Arshad M. Khanani, MD, MA
THE DAVIO 2 TRIAL: Topline Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration by Charles C. Wykoff, MD, PhD
96-week Efficacy and Safety of Aflibercept 8 mg in nAMD: An Update from the PULSAR Study by W. Lloyd Clark, MD
Faricimab in RVO: 72-Week Results From the BALATON and COMINO Phase 3 Studies by Ramin Tadayoni, MD, PhD
First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD by Arshad M. Khanani, MD, MA ►